Extended Data Fig. 3: Concurrent alterations in tumor.
From: Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Shown are concurrent alterations observed by retrospective molecular profiling of archival tumor tissue (FoundationOne CDx). Each patient with available data is represented by a column. The colored rectangles above each column represent the best objective response to crizotinib. Within a column, each gene of interest for which a concurrent alteration is present is represented by a colored rectangle corresponding to the alteration type. Concurrent genomic alterations (average number of alterations per patient was 4.3 (range, 0 to 12)) were identified in tumor tissue from 35 of 40 (88%) patients with analyzable samples. MDM2 amplification was detected in non-responders, but not observed in responders. No notable response differences were seen in relation to absence or presence of TP53 mutation. AMP, amplification. SNV, single-nucleotide variant.
